|
|
Article: Romark Laboratories Raises $18 Million in Institutional Financing.
- Article from:
- PR Newswire
- Article date:
- December 21, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla., Dec. 21 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biotechnology company, today announced the closing of an $18 million institutional financing with the D.E. Shaw Group.
The proceeds from this financing will enable Romark to advance development of its lead compound, nitazoxanide, for the treatment of hepatitis C, and advance its next-generation thiazolide drug candidates for the treatment of hepatitis B and C and other viral diseases. Romark is currently conducting a U.S. Phase 2 trial of nitazoxanide in hepatitis C patients who have failed standard treatments, and expects to begin a U.S. Phase 2 trial in treatment naive patients ...